Compass Therapeutics (CMPX) said Tuesday topline data from an ongoing phase 2/3 trial of tovecimig combined with paclitaxel in biliary tract cancer showed 'statistically significant' improvement in overall response rate, indicating it has met the trial's primary efficacy endpoint.
The drug combination achieved a 17.1% ORR, including one complete response, versus 5.3% for paclitaxel alone.
The secondary endpoints including progression-free survival, overall survival, and duration of response-could not be analyzed yet due to insufficient events, with data expected in Q4, the company said.
Shares rose 11% in recent premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。